Satellos Bioscience Inc. (MSLE)
MSLE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | MSLE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001421642 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Canada |
| Canadian listing | TSX: MSCL |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 40-F 2026-03-27 |
| Cash and burn | $9.8M cash; operating cash flow -$5.9M a quarter. | Report 2025-12-31 |
| Shares outstanding | 15,458,903 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 1; latest 1-for-12 on 2026-01-30 | Source 2026-01-30 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Toronto, Canada | PCAOB Form AP 2026-04-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$24.9M | -$23.6M | $9.8M | No debt tags | Needs four quarters | 40-F 2026-03-27 |
| FY 2024 2024-12-31 | Not filed | -$20.6M | -$18.3M | $40.1M | No debt tags | Needs four quarters | 40-F 2026-03-27 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 40-F | 2026-03-27 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 56 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.9% |
| 1 month | -5.9% |
| 3 months | -32.5% |
| Year to date | +12.7% |
| 1 year | +10.4% |
| From 52-week high | -49.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MGNX | MacroGenics Inc. | $2.17 | -1.36% | $138.7M |
| RNA | Atrium Therapeutics Inc. | $6.43 | -14.38% | $138.7M |
| MENS | Jyong Biotech Ltd. | $1.77 | +0.57% | $134.6M |
| SION | Sionna Therapeutics Inc. | $3.12 | -6.31% | $141.1M |
| NTHI | NeOnc Technologies Holdings Inc. | $4.54 | -7.54% | $131.0M |
| CNTN | Canton Strategic Holdings Inc. | $1.64 | -4.09% | $130.7M |
| VRXA | Veraxa Biotech AG | $1.04 | -5.86% | $147.8M |
| ABEO | Abeona Therapeutics Inc. | $2.60 | +7.44% | $148.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier